Management of lipid disorders for stroke prevention

Journal of Neuroscience Nursing

Volumn 38, Issue 4, 2006, Pages 282-295

  Fowler, Susan B ^b   Kelly, Marty ^c   Ruh, Donna ^c   Johnson Wells, Deborah ^a  

^a Morristown Memeorial Hospital ^*

^b Morristown Hospital   (United States)

^c Somerset Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT;

CEREBROVASCULAR ACCIDENT; DYSLIPIDEMIA; HUMAN; LIFESTYLE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; RISK;

ANTICHOLESTEREMIC AGENTS; CEREBROVASCULAR ACCIDENT; DYSLIPIDEMIAS; HUMANS; LIFE STYLE; PRACTICE GUIDELINES; RISK;

EID: 33750132027     PISSN: 08880395     EISSN: None     Source Type: Journal    
DOI: 10.1097/01376517-200609000-00003     Document Type: Article

References (32)

1. Amarenco, P., Labreuche, J. B., Lavallee, P. B., & Touboul, P. J. (2004). Statins in stroke prevention and carotid atherosclerosis. Systematic review and up-to-date meta-analysis. Stroke, 35, 2902-2909.
2. American College of Sports Medicine. (2005). Guidelines for healthy aerobic activity. Retrieved January 20, 2006, from www.acsm.org.
3. American Stroke Association Stroke Council. (2004). Statins after isch-emic stroke and transient ischemic attack: An advisory statement from the Stroke Council, American Heart Association and American Stroke Association. Stroke, 35, 1023.
4. Boots, J. M., Christiaans, M. H., & van Hooff, J. P. (2004). Effect of immunosuppressive agents on long-term survival of renal transplant recipients: Focus on the cardiovascular risk. Drugs, 64, 2047-2073.
5. Bryan, R. H. (2004). Controlling cholesterol. Advance for Nursing, 4, 41-, 47.
6. Burke, L. E., Dunbar-Jacob, J., Sereika, S., & Ewart, C. K. (2003). Development and testing of the Cholesterol-Lowering Diet Self-Efficacy Scale. European Journal of Cardiovascular Nursing, 2, 265-273.
7. DiNapoli, P., Taccardi, A. A., Oliver, M., & DeCaterina, R. (2002). Statins and stroke: Evidence for cholesterol-independent effects. European Heart Journal, 23, 1908-1921.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (2001). Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal of the American Medical Association, 285, 2486-2497.
9. Farmer, J., & Gotto, A. M., Jr. (2002). Dyslipidemia and the vulnerable plaque. Progress in Cardiovascular Diseases, 5, 415-427.
10. Forrester, J. (2002). Prevention of plaque rupture: A new paradigm of therapy. Annals of Internal Medicine, 137, 823-833.
11. Fowler, S. B., Moussouttas, M., & Mancini, B. (2005). Metabolic syndrome: Contributing factors and treatment strategies. Journal of Neuroscience Nursing, 37, 220-223.
12. Futterman, L. G., & Lemberg, L. (1999). Stroke risk, cholesterol, and statins. American Journal of Critical Care, 5, 416-419.
13. Gomes, J. A., Robins, S. J., & Babikian, V L. (2002). Treatment of lipid disorders after stroke. Current Atherosclerosis Reports, 4, 304-310.
14. Gotto, A., & Pownall, H. (1999). Manual of lipid disorders (2nd ed.). Baltimore: Lippincott, Williams & Williams.
15. Graham, D. J., Staffa, J. A., Shatin, D., Andrade, S.E., Schech, S. D., La Grenade, L., et al. (2004). Incidence of hospitalized rhabdomy-olysis in patients treated with lipid-lowering drugs. Journal of the American Medical Association, 292, 2585-2590.
16. Learelle, D. E. (2001). Mayo medical laboratory interpretive handbook. Rochester, MN: Mayo Clinic.
17. Lockman, A. R., Tribastone, A. D., Knight, K. V., & Franko, J. P. (2005). Treatment of cholesterol abnormalities. American Family Physician, 71, 1137-1142.
18. Mantel-Teeuwisse, A. K., Kloosterman, J. M., Maitland-van der Zee, A. H., Klungel, O. H., Porsius, A. J., & de Boer, A. (2001). Drug-induced lipid changes: A review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Safety, 24, 443-456.
19. Mayo Clinic (n.d.). Beta Blockers. Retrieved July 31, 2006, from www. mayoclinicl.com/health/beta-blockers/HI00059.
20. McDonald, K. (2003). Lipid-lowering strategies: Today’s therapies and co-therapies can reduce CHD risk. Advance for Nurse Practitioners, 11(12), 24-29.
21. Merck & Co, Inc. (2005). Hyperlipoproteinemia. Retrieved July 31, 2006, from www.merck.com/mmhe/au/sec12/ch157/ch157b.html.
22. Miller, M. (2003). Niacin as a component of combination therapy for dyslipidemia. Mayo Clinical Proceedings, 78, 735-742.
23. Moon, Y. S., & Kashyap, M. L. (2004). Pharmacologic treatment of type-2 diabetic dyslipidemia. Pharmacotherapy, 24, 1692-1713.
24. Moran, M. (2004). Statins: Do the risks outweigh the benefits? Neurology Today, 4, 28-31.
25. Mouradian, M. S., Majumdar, S. R., Senthilselvan, A., Khan, K., & Shuaib, A. (2002). How well are hypertension, hyperlipidemia, diabetes, and smoking managed after a stroke or transient isch-emic attack? Stroke, 33, 1656-1659.
26. Shah, P. (2002). Pathophysiology of coronary thrombosis: Role of plaque rupture and plaque erosion. Progress in Cardiovascular Disease, 5, 357-368.
27. Thompson, P. D., Clarkson, P., & Karas, R. H. (2003). Statin-associated myopathy. Journal of the American Medical Association, 289, 1681-1690.
28. Toth, P. (2004). High-density lipoprotein and cardiovascular risk. Circulation, 109, 1809-1812.
29. Wannamethee, S. G., Shaper, A. G., & Ebrahim, S. (2000). HDL cholesterol, total cholesterol, and the risk of stroke in middle-aged British men. Stroke, 31, 1882-1888.
30. Wierzbicki, A. S., Mikhailidis, D. P., Wray, R., Schacter, M., Cramb, R., Simpson, W. G., et al. (2003). Statin-fibrate combination: Therapy for hyperlipidemia-A review. Current Medical Research and Opinion, 19, 155-168.
31. Wittert, D. D. (2004a, May 17). Cholesterol: The good, the bad, and the balanced: Part 1-Assessment. Nursing Spectrum, 17(NY/NJ), 28-30.
32. Wittert, D. D. (2004b, June 1). Cholesterol: The good, the bad, and the balanced: Part 2-Treatment. Nursing Spectrum, 17(NY/NJ), 24-26.